These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21104470)

  • 1. Kras in metastatic colorectal cancer.
    Wicki A; Herrmann R; Christofori G
    Swiss Med Wkly; 2010; 140():w13112. PubMed ID: 21104470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
    Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
    Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H; Eshima K
    Eur J Cancer; 2011 Sep; 47(13):1946-54. PubMed ID: 21531130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Shibuya H; Eshima K
    Dis Colon Rectum; 2011 Sep; 54(9):1170-8. PubMed ID: 21825899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
    Chen J; Ye Y; Sun H; Shi G
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
    Hecht JR; Douillard JY; Schwartzberg L; Grothey A; Kopetz S; Rong A; Oliner KS; Sidhu R
    Cancer Treat Rev; 2015 Sep; 41(8):653-9. PubMed ID: 26220150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma.
    Natalicchio MI; Improta G; Zupa A; Cursio OE; Stampone E; Possidente L; Teresa Gerardi AM; Vita G; Martini M; Cassano A; Piccoli C; Romito S; Aieta M; Antonetti R; Barone C; Landriscina M
    Future Oncol; 2014 Apr; 10(5):713-23. PubMed ID: 24799053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
    Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M
    Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.
    Wang HL; Lopategui J; Amin MB; Patterson SD
    Adv Anat Pathol; 2010 Jan; 17(1):23-32. PubMed ID: 20032635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.